A Phase II Trial to Assess the Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Trial Profile

A Phase II Trial to Assess the Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Panitumumab (Primary) ; Cisplatin; Docetaxel
  • Indications Adenocarcinoma; Gastric cancer; Gastrointestinal cancer
  • Focus Therapeutic Use
  • Acronyms SPIGA
  • Most Recent Events

    • 10 Mar 2015 Planned End Date changed from 1 Apr 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
    • 10 Mar 2015 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 24 Jan 2015 Status changed from recruiting to completed, according to European Clinical Trials Database
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top